The novel coronavirus SARS-CoV-2 has an enzyme that can counteract a cell's innate defense mechanism against viruses, explaining why it is more infectious than the previous SARS and MERS-causing viruses.
Kobe UniversityOct 22 2024 The novel coronavirus SARS -CoV-2 has an enzyme that can counteract a cell's innate defense mechanism against viruses, explaining why it is more infectious than the previous SARS and MERS-causing viruses. The Kobe University discovery may point the way to the development of more effective drugs against this and possibly similar, future diseases.
Shoji's team previously worked on the immune response to hepatitis viruses and investigated the role of a molecular tag called "ISG15" the innate immune system attaches to the virus's building blocks. Having learned that the novel coronavirus has an enzyme that is especially effective in removing this tag, he decided to use his team's expertise to elucidate the effect of the ISG15 tag on the coronavirus and the mechanism of the virus's countermeasures.
The novel coronavirus shares many traits with the SARS and MERS viruses, which all belong to the same family of viruses. And these viruses, too, have an enzyme that can remove the ISG15 tag. However, Shoji's team found that their versions are less efficient at it than the one in the novel coronavirus. And in fact, it has been reported recently that the previous viruses' enzymes have a different primary target.
Immune Response Cell Drugs Enzyme Genetic Immune System Pathogen Protein Research SARS SARS-Cov-2 Technology Virology Virus
United Kingdom Latest News, United Kingdom Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Antiviral drug molnupiravir linked to new mutations in SARS-CoV-2Molnupiravir, an antiviral drug used to treat patients with COVID-19, appears to be driving SARS-CoV-2 to mutate and evolve, with some of these new viruses being transmitted onwards, a new study has shown.
Read more »
New study links persistent SARS-CoV-2 proteins to long COVID symptomsBrigham researchers found people with wide-ranging long COVID symptoms were twice as likely to have SARS-CoV-2 proteins in their blood, compared to those without long COVID symptoms.
Read more »
Two studies find SARS-CoV-2 virus becoming resistant to antiviral drugs used to treat patientsTwo studies have found that the virus that causes COVID-19 is becoming resistant to two drugs used to treat patients with infections.
Read more »
Antigenic mapping sheds light on SARS-CoV-2 immunity differencesA person's immune response to variants of SARS-CoV-2, the virus that causes COVID-19, depends on their previous exposure - and differences in the focus of immune responses will help scientists understand how to optimise vaccines in the future to provide broad protection.
Read more »
De novo antibody protein sequencing reveals novel functional and neutralizing antibodies Post-SARS-CoV-2 vaccinationRapid Novor has published a study that highlights the power of combining de novo antibody protein sequencing with conventional proteomics to uncover functional and neutralizing antibodies in human plasma following SARS-CoV-2 vaccination.
Read more »
Research reveals a disconnect between patient expectations and care for long COVID'Long COVID' is the continuation or development of new symptoms three months after initial SARS-CoV-2 infection.
Read more »